Anticancer research · 2026
Preoperative Serum Total Cholesterol Predicts Adjuvant Chemotherapy Completion After Pancreaticoduodenectomy for Pancreatic Cancer.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hatta Kosuke, Nishimura Sadaaki, Tanaka Ryota, Shinkawa Hiroji, Nishio Kohei, Kinoshita Masahiko, Tauchi Jun, Kurihara Shigeaki, Ishizawa Takeaki
Аннотация
BACKGROUND/AIM: Completion of adjuvant chemotherapy (AC) is a key determinant of long-term survival after curative-intent resection for pancreatic cancer. However, predictors of AC completion remain unclear. This study aimed to clarify the prognostic significance of AC non-completion and identify host-related factors after pancreaticoduodenectomy (PD).
PATIENTS AND METHODS: We retrospectively analyzed 170 patients who were scheduled to receive AC after PD for pancreatic cancer. Associations between AC completion status and survival outcomes were evaluated. Independent predictors of AC non-completion were identified using logistic regression, and model performance was assessed through receiver operating characteristic analysis, calibration plots, and decision curve analysis (DCA).
RESULTS: Of the 170 patients, 116 (68.2%) completed standard AC (complete group), whereas 54 (31.8%) discontinued treatment (incomplete group). The 5-year survival rate was significantly lower in the incomplete group than in the complete group (16.7% vs. 45.3%, p<0.001). Low serum total cholesterol (T-chol) independently predicted poor AC tolerance. The T-chol model demonstrated moderate discrimination (area under the curve: 0.697) and good calibration. DCA indicated a favorable net clinical benefit for T-chol within a threshold probability range of 0.2-0.4.
CONCLUSION: Serum T-chol is a strong predictor of AC completion and may help identify patients with pancreatic cancer who could benefit from targeted nutritional or supportive interventions during the perioperative period.
PATIENTS AND METHODS: We retrospectively analyzed 170 patients who were scheduled to receive AC after PD for pancreatic cancer. Associations between AC completion status and survival outcomes were evaluated. Independent predictors of AC non-completion were identified using logistic regression, and model performance was assessed through receiver operating characteristic analysis, calibration plots, and decision curve analysis (DCA).
RESULTS: Of the 170 patients, 116 (68.2%) completed standard AC (complete group), whereas 54 (31.8%) discontinued treatment (incomplete group). The 5-year survival rate was significantly lower in the incomplete group than in the complete group (16.7% vs. 45.3%, p<0.001). Low serum total cholesterol (T-chol) independently predicted poor AC tolerance. The T-chol model demonstrated moderate discrimination (area under the curve: 0.697) and good calibration. DCA indicated a favorable net clinical benefit for T-chol within a threshold probability range of 0.2-0.4.
CONCLUSION: Serum T-chol is a strong predictor of AC completion and may help identify patients with pancreatic cancer who could benefit from targeted nutritional or supportive interventions during the perioperative period.